Format
Items per page
Sort by

Send to:

Choose Destination

Search results

Items: 1 to 20 of 80

1.

Promising Oral Compounds for the Treatment of Multiple Sclerosis: A Glance into the Future.

Décard BF, Derfuss T.

Semin Neurol. 2016 Apr;36(2):128-39. doi: 10.1055/s-0036-1580720. Epub 2016 Apr 26.

PMID:
27116719
2.

Natalizumab-induced POU2AF1/Spi-B upregulation: A possible route for PML development.

Meira M, Sievers C, Hoffmann F, Haghikia A, Rasenack M, Décard BF, Kuhle J, Derfuss T, Kappos L, Lindberg RL.

Neurol Neuroimmunol Neuroinflamm. 2016 Mar 31;3(3):e223. doi: 10.1212/NXI.0000000000000223. eCollection 2016 Jun.

3.

Multiple Sclerosis and Antibodies against KIR4.1.

Pröbstel AK, Kuhle J, Lecourt AC, Vock I, Sanderson NS, Kappos L, Derfuss T.

N Engl J Med. 2016 Apr 14;374(15):1496-8. doi: 10.1056/NEJMc1507131. No abstract available.

PMID:
27074084
4.

Comparison of three analytical platforms for quantification of the neurofilament light chain in blood samples: ELISA, electrochemiluminescence immunoassay and Simoa.

Kuhle J, Barro C, Andreasson U, Derfuss T, Lindberg R, Sandelius Å, Liman V, Norgren N, Blennow K, Zetterberg H.

Clin Chem Lab Med. 2016 Apr 12. pii: /j/cclm.ahead-of-print/cclm-2015-1195/cclm-2015-1195.xml. doi: 10.1515/cclm-2015-1195. [Epub ahead of print]

PMID:
27071153
5.

The Swiss Multiple Sclerosis Cohort-Study (SMSC): A Prospective Swiss Wide Investigation of Key Phases in Disease Evolution and New Treatment Options.

Disanto G, Benkert P, Lorscheider J, Mueller S, Vehoff J, Zecca C, Ramseier S, Achtnichts L, Findling O, Nedeltchev K, Radue EW, Sprenger T, Stippich C, Derfuss T, Louvion JF, Kamm CP, Mattle HP, Lotter C, Du Pasquier R, Schluep M, Pot C, Lalive PH, Yaldizli Ö, Gobbi C, Kappos L, Kuhle J; SMSC Scientific Board.

PLoS One. 2016 Mar 31;11(3):e0152347. doi: 10.1371/journal.pone.0152347. eCollection 2016.

6.

Severe exacerbation of relapsing-remitting multiple sclerosis after G-CSF therapy.

Rust H, Kuhle J, Kappos L, Derfuss T.

Neurol Neuroimmunol Neuroinflamm. 2016 Mar 9;3(2):e215. doi: 10.1212/NXI.0000000000000215. eCollection 2016 Apr. No abstract available.

7.

Disease activity return after natalizumab cessation in multiple sclerosis.

Rasenack M, Derfuss T.

Expert Rev Neurother. 2016 May;16(5):587-94. doi: 10.1586/14737175.2016.1168295. Epub 2016 Apr 6.

PMID:
26988737
8.

Serum neurofilament light chain in early relapsing remitting MS is increased and correlates with CSF levels and with MRI measures of disease severity.

Kuhle J, Barro C, Disanto G, Mathias A, Soneson C, Bonnier G, Yaldizli Ö, Regeniter A, Derfuss T, Canales M, Schluep M, Du Pasquier R, Krueger G, Granziera C.

Mult Scler. 2016 Jan 11. pii: 1352458515623365. [Epub ahead of print]

PMID:
26754800
9.

Efficacy and Safety of Fingolimod in an Unselected Patient Population.

Rasenack M, Rychen J, Andelova M, Naegelin Y, Stippich C, Kappos L, Lindberg RL, Sprenger T, Derfuss T.

PLoS One. 2016 Jan 6;11(1):e0146190. doi: 10.1371/journal.pone.0146190. eCollection 2016.

10.

Optimizing treatment success in multiple sclerosis.

Ziemssen T, Derfuss T, de Stefano N, Giovannoni G, Palavra F, Tomic D, Vollmer T, Schippling S.

J Neurol. 2015 Dec 24. [Epub ahead of print]

PMID:
26705122
11.

Pro-inflammatory pattern of IgG1 Fc glycosylation in multiple sclerosis cerebrospinal fluid.

Wuhrer M, Selman MH, McDonnell LA, Kümpfel T, Derfuss T, Khademi M, Olsson T, Hohlfeld R, Meinl E, Krumbholz M.

J Neuroinflammation. 2015 Dec 18;12:235. doi: 10.1186/s12974-015-0450-1.

12.

Immunologic monitoring during a phase 2a trial of the GNbAC1 antibody in patients with MS.

Zimmermann M, Sanderson NS, Rasenack M, Lalive PH, Lang AB, Curtin F, Lindberg RL, Kappos L, Derfuss T.

Neurol Neuroimmunol Neuroinflamm. 2015 Aug 20;2(5):e144. doi: 10.1212/NXI.0000000000000144. eCollection 2015 Oct.

13.

Optimizing treatment initiation: Effects of a patient education program about fingolimod treatment on knowledge, self-efficacy and patient satisfaction.

Zimmer A, Bläuer C, Coslovsky M, Kappos L, Derfuss T.

Mult Scler Relat Disord. 2015 Sep;4(5):444-50. doi: 10.1016/j.msard.2015.06.010. Epub 2015 Jun 19.

PMID:
26346793
14.

A phase IIa randomized clinical study testing GNbAC1, a humanized monoclonal antibody against the envelope protein of multiple sclerosis associated endogenous retrovirus in multiple sclerosis patients - a twelve month follow-up.

Derfuss T, Curtin F, Guebelin C, Bridel C, Rasenack M, Matthey A, Du Pasquier R, Schluep M, Desmeules J, Lang AB, Perron H, Faucard R, Porchet H, Hartung HP, Kappos L, Lalive PH.

J Neuroimmunol. 2015 Aug 15;285:68-70. doi: 10.1016/j.jneuroim.2015.05.019. Epub 2015 May 20.

PMID:
26198921
15.

B Cells and Autoantibodies in Multiple Sclerosis.

Pröbstel AK, Sanderson NS, Derfuss T.

Int J Mol Sci. 2015 Jul 21;16(7):16576-92. doi: 10.3390/ijms160716576. Review.

16.

Efficacy of fingolimod in patients with highly active relapsing-remitting multiple sclerosis.

Derfuss T, Bergvall NK, Sfikas N, Tomic DL.

Curr Med Res Opin. 2015;31(9):1687-91. doi: 10.1185/03007995.2015.1067191. Epub 2015 Aug 20.

PMID:
26121423
17.

Switching from natalizumab to fingolimod: A randomized, placebo-controlled study in RRMS.

Kappos L, Radue EW, Comi G, Montalban X, Butzkueven H, Wiendl H, Giovannoni G, Hartung HP, Derfuss T, Naegelin Y, Sprenger T, Mueller-Lenke N, Griffiths S, von Rosenstiel P, Gottschalk R, Zhang Y, Dahlke F, Tomic D; TOFINGO study group.

Neurology. 2015 Jul 7;85(1):29-39. doi: 10.1212/WNL.0000000000001706. Epub 2015 May 29.

18.

Anti-MOG antibodies are present in a subgroup of patients with a neuromyelitis optica phenotype.

Pröbstel AK, Rudolf G, Dornmair K, Collongues N, Chanson JB, Sanderson NS, Lindberg RL, Kappos L, de Seze J, Derfuss T.

J Neuroinflammation. 2015 Mar 8;12:46. doi: 10.1186/s12974-015-0256-1.

19.

A pragmatic approach to dealing with fingolimod-related lymphopaenia in Europe.

Giovannoni G, de Jong B, Derfuss T, Izquierdo G, Mazibrada G, Molyneux P, Nicholas R, Overell J, Ziemssen T, Juliusson G.

Mult Scler Relat Disord. 2015 Jan;4(1):83-4. doi: 10.1016/j.msard.2014.09.215. Epub 2014 Oct 13. No abstract available.

PMID:
25787058
20.

Conversion from clinically isolated syndrome to multiple sclerosis: A large multicentre study.

Kuhle J, Disanto G, Dobson R, Adiutori R, Bianchi L, Topping J, Bestwick JP, Meier UC, Marta M, Dalla Costa G, Runia T, Evdoshenko E, Lazareva N, Thouvenot E, Iaffaldano P, Direnzo V, Khademi M, Piehl F, Comabella M, Sombekke M, Killestein J, Hegen H, Rauch S, D'Alfonso S, Alvarez-Cermeño JC, Kleinová P, Horáková D, Roesler R, Lauda F, Llufriu S, Avsar T, Uygunoglu U, Altintas A, Saip S, Menge T, Rajda C, Bergamaschi R, Moll N, Khalil M, Marignier R, Dujmovic I, Larsson H, Malmestrom C, Scarpini E, Fenoglio C, Wergeland S, Laroni A, Annibali V, Romano S, Martínez AD, Carra A, Salvetti M, Uccelli A, Torkildsen Ø, Myhr KM, Galimberti D, Rejdak K, Lycke J, Frederiksen JL, Drulovic J, Confavreux C, Brassat D, Enzinger C, Fuchs S, Bosca I, Pelletier J, Picard C, Colombo E, Franciotta D, Derfuss T, Lindberg R, Yaldizli Ö, Vécsei L, Kieseier BC, Hartung HP, Villoslada P, Siva A, Saiz A, Tumani H, Havrdová E, Villar LM, Leone M, Barizzone N, Deisenhammer F, Teunissen C, Montalban X, Tintoré M, Olsson T, Trojano M, Lehmann S, Castelnovo G, Lapin S, Hintzen R, Kappos L, Furlan R, Martinelli V, Comi G, Ramagopalan SV, Giovannoni G.

Mult Scler. 2015 Jul;21(8):1013-24. doi: 10.1177/1352458514568827. Epub 2015 Feb 13.

PMID:
25680984
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk